Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN UFH versus LIQUAEMIN LOCK FLUSH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN UFH versus LIQUAEMIN LOCK FLUSH.
Heparin (UFH) vs LIQUAEMIN LOCK FLUSH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, inducing a conformational change that accelerates the inactivation of thrombin (factor IIa) and factor Xa, thereby inhibiting coagulation.
Heparin potentiates the activity of antithrombin III, thereby inactivating thrombin (factor IIa) and activated factor X (Xa), and preventing fibrin clot formation. It also inhibits factors IXa, XIa, and XIIa.
Intravenous: Initial bolus of 80 units/kg (or 5000 units) followed by continuous infusion of 18 units/kg/h (or 1300 units/h), adjusted to maintain aPTT 1.5-2.5 times control. Subcutaneous: 5000 units every 8-12 hours for prophylaxis.
10-100 units/mL solution; flush intermittent intravenous catheters after each use with 1-5 mL; for central venous catheters, use 2-3 mL of 10 units/mL solution; for peripheral catheters, use 1-2 mL of 10 units/mL solution.
None Documented
None Documented
0.5–2 hours (dose-dependent; at therapeutic doses, ~1–2 h; with higher doses, up to 2.5 h). Clinical context: shorter half-life in pulmonary embolism; prolonged in hepatic or renal impairment.
1-2 hours (dose-dependent; prolonged with higher doses, renal impairment, or in elderly).
Primarily cleared via reticuloendothelial system and metabolism; renal excretion of unchanged drug is minimal (<5%).
Renal (predominantly via reticuloendothelial system and liver metabolism; unchanged drug excreted in urine).
Category A/B
Category C
Anticoagulant
Anticoagulant